We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Actavis Extends Namenda Shelf Time Amid Generic-Delay Lawsuit
Actavis Extends Namenda Shelf Time Amid Generic-Delay Lawsuit
Actavis said it will continue marketing the original formulation of its blockbuster Alzheimer’s drug Namenda for 60 days longer than originally planned, as the drugmaker faces antitrust allegations over its plans to withdraw the product in favor of a newer version.